BioStem Secures Hospital Access for Wound Care Products via Vizient and Premier Contracts
Event summary
- BioStem's VENDAJE® and VENDAJE AC® added to Vizient and Premier GPO contracts effective September 4, 2026.
- Vizient serves 5,000+ hospitals; Premier serves 4,000+ hospitals.
- First GPO contract coverage for these placental-derived wound care products.
- Products manufactured using BioStem's proprietary BioRetain® process.
The big picture
This GPO expansion positions BioStem to scale its wound care solutions across 9,000+ hospitals, addressing a critical access barrier. The move reflects broader industry trends toward consolidated procurement in healthcare, where GPO partnerships can significantly accelerate product adoption. Success will depend on BioStem's ability to differentiate its placental-derived allografts in a competitive regenerative medicine landscape.
What we're watching
- Market Penetration
- How quickly BioStem can convert GPO access into actual hospital orders and revenue growth.
- Competitive Response
- Whether competitors in regenerative wound care will seek similar GPO partnerships to maintain market share.
- Product Differentiation
- The extent to which BioStem's proprietary BioRetain® process can sustain a competitive advantage in placental tissue products.
Related topics